qPCR

The firm's CFO said that the timing of revenue recognition on the Beacon carrier screening test prevented Fulgent from recording revenues from the tests in Q4.

The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.

The test is designed to detect and differentiate herpes simplex virus types 1 and 2, Treponema pallidum, and varicella-zoster virus.

GenomeDx will have exclusive rights to distribute the molecular tests in most of the US, while Pathnostics continues to perform the assays in-house.

Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.